Rezpegaldesleukin (NKTR-358) in New Onset Type 1 Diabetes Mellitus
Public ClinicalTrials.gov record NCT07142252. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This Phase 2 study is a 2-arm, multi-center, double-masked (masking of the participant, care provider and investigator), placebo-controlled, 2:1 randomized trial design in new onset T1D participants (within 100 days of diagnosis). Participants will be administered rezpegaldesleukin/placebo once every 14 days over 26 weeks with an additional 6-month follow-up period.
Study identification
- NCT ID
- NCT07142252
- Recruitment status
- Recruiting
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 66 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 8 Years to 45 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- May 14, 2026 (Actual)
- Primary completion
- May 25, 2028 (Estimated)
- Completion
- May 25, 2028 (Estimated)
- Last update posted
- Sep 8, 2026
2026 – 2028
United States locations
- U.S. sites
- 14
- U.S. states
- 12
- U.S. cities
- 14
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| University of California San Francisco | San Francisco | California | 94158 | Recruiting |
| Barbara Davis Center for Diabetes | Aurora | Colorado | 80045 | Recruiting |
| Yale University | New Haven | Connecticut | 06520 | Recruiting |
| University of Florida | Gainesville | Florida | 32610 | Recruiting |
| University of Miami | Miami | Florida | 33136 | Recruiting |
| USF Diabetes Center | Tampa | Florida | 33612 | Recruiting |
| Indiana University-Riley Hospital for Children | Indianapolis | Indiana | 46202 | Recruiting |
| Joslin Diabetes Center | Boston | Massachusetts | 02115 | Recruiting |
| University of Minnesota | Minneapolis | Minnesota | 55455 | Recruiting |
| Columbia University | New York | New York | 10032 | Recruiting |
| University of Pittsburgh | Pittsburgh | Pennsylvania | 15224 | Recruiting |
| Vanderbilt University | Nashville | Tennessee | 37232 | Recruiting |
| University of Utah | Salt Lake City | Utah | 84113 | Recruiting |
| Benaroya Research Institute | Seattle | Washington | 98101 | Recruiting |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 1 non-U.S. site.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT07142252, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Sep 8, 2026 · Synced Oct 17, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT07142252 live on ClinicalTrials.gov.